A new paradigm in managing advanced ovarian cancer: differentiating patients requiring neoadjuvant treatment from primary cytoreduction - Université de Lille Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2021

A new paradigm in managing advanced ovarian cancer: differentiating patients requiring neoadjuvant treatment from primary cytoreduction

Résumé

Our study aims to evaluate the comparability of primary debulking surgery (PDS) and neoadjuvant chemotherapy (NACT) patients. This single-center retrospective study includes all patients treated for advanced stages high-grade serous ovarian carcinomas (HGSOC) between 2007 and 2017. Preoperative characteristics and postoperative outcomes were compared after a propensity score matching analysis. Of the 221 patients included, 38% underwent PDS, and 62% received NACT. There was no age difference at diagnosis; however, CA125 levels, PCI score levels, and rates of stage IV were higher in the NACT group. There were no differences concerning the rate and the severity of complications (p = 0.29). The propensity score distribution showed a broad distinction between PDS patients and NACT patients with no significant overlap. Survival analyses demonstrate, after a median follow-up of 66.5 months, an overall survival (OS) of 105.9 and progression-free survival (PFS) of 29.2 months in the PDS group, compared to OS of 52.8 and PFS of 18.9 months in the NACT group. Advanced HGSOC is a heterogeneous population, in which inoperable patients should be differentiated from PDS patients based on many factors, primarily tumor burden.
Fichier principal
Vignette du fichier
cancers-13-04925.pdf (761.91 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03934175 , version 1 (11-01-2023)

Licence

Paternité

Identifiants

Citer

Francois Kraus, Houssein El Hajj, Marie-Cecile Le Deley, Othman Aissaoui, Bertrand Gachon, et al.. A new paradigm in managing advanced ovarian cancer: differentiating patients requiring neoadjuvant treatment from primary cytoreduction. Cancers, 2021, Cancers, 13 (19), pp.4925. ⟨10.3390/cancers13194925⟩. ⟨hal-03934175⟩
11 Consultations
10 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More